Description: Letter from the Editor

Description: Summary of the 2016 SOA Health Meeting in Philadelphia, PA

Description: Read the March 2017 issue of Health Watch, published by the Health Section. Practical information for actuaries, articles impact sections, section activities.

Description: Hear from the chairperson on themes in the March 2017 issue of Health Watch, published by the Health Section.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: This article examines the dynamic environment of the health care system in the United States and the challenges facing the health actuary.

Description: Answers to questions that have surfaced with regard to recent trends in the use of psychiatric medications, including relative effectiveness compared to prescribing patterns, drivers of prescribing patterns, classification and indications for recently publicized drugs, role of primary care providers, preventive use ofdementia medications, and new developments in the field.

Description: Health Section News, August 2005, Issue 50 which discusses the effective management of prescription drug utilization and coverage that continue to represent one of the biggest challenges facing insurers, managed care organizations, employers and consumers alike.

Description: Overview of a benefit rush and its effects on companies.